NCT05385952已完成不适用
A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 132
- 试验地点
- 10
- 主要终点
- Rate of Hemostasis at 3 Minutes Without Rebleeding at the 10-minute Time Point
研究概览
简要总结
This is a pre-market, prospective, randomized (2:1), multicenter, multi-national pivotal clinical investigation. The purpose of this investigation is to determine the clinical safety and performance of GATT-Patch as compared with TachoSil for the management of minimal, mild, or moderate bleeding during elective open liver surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Patients will be blinded to randomized treatment and treatment used.
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is scheduled to undergo elective open surgery on the liver;
- •Subject is willing and able to give written informed consent for the clinical investigation participation;
- •Subjects is 22 years of age or older at the time of enrollment; and
- •Subject has been informed of the nature of the clinical investigation.
- •A subject must meet all of the following intra-operative inclusion criteria to be enrolled into the clinical investigation:
- •Subject in whom the Investigator is able to identify a target bleeding site at the liver resection plane for which any applicable conventional means for hemostasis (e.g. suture, ligature or cautery) are ineffective or impractical, and the choice is made to use a hemostatic agent to stop the bleeding; and
- •Subject has a target bleeding site with a SBSS of 1, 2, or 3 (e.g. reflecting minimal, mild or moderate bleeding severities).
排除标准
- •The target bleeding site is from a large defect in an artery or vein that requires vascular reconstruction with maintenance of vessel patency;
- •Subject is scheduled to undergo surgery on other organs than the liver and its associated biliary and vascular system; • Subject is scheduled to undergo a staged liver surgery procedure (e.g., Associating Liver Partition and Portal vein ligation for Staged hepatectomy [ALPPS])
- •Subject is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, but allowing exclusive use of acetylsalicylic acid;
- •Subject has platelet count <100 x 109/L, an activated partial thrombin time of >100s, or international normalized ratio >2.5;
- •Subject has a total bilirubin level of ≥2.5 mg/dl;
- •Subject is pregnant, planning on becoming pregnant or actively breastfeeding during the 3-month follow-up period;
- •Subject has a known hypersensitivity to brilliant blue (FD&C Blue #1), porcine gelatin, or horse proteins;
- •Subject who has religious objections to receiving products with components of animal (porcine or equine) or human origin;
- •Subject has an active or suspected infection at the bleeding site;
- •Subject in whom the investigational device will be used at the site of a synthetic graft or patch implant;
- •Subject has a life expectancy of less than 3 months;
- •Subject has a documented severe congenital or acquired immunodeficiency;
- •Subject has had or has planned to receive any organ transplantation;
- •Subject undergoes surgery with the indication of being a living liver donor;
- •Subject is currently participating or has participated in another clinical investigation within the past 30 days that may affect the endpoints of the study, such as trials related to the surgical procedure, and on anti-coagulation;
- •Subject is not appropriate for inclusion in the clinical investigation, per the medical opinion of the Investigator; and
- •Subject has any incidental (pre- and peri-operative) findings deemed by the Investigator to potentially jeopardize the safety or welfare of the subject.
研究组 & 干预措施
TachoSil
Active Comparator
Hemostatic patch
干预措施: TachoSil (Drug)
GATT-Patch (currently named ETHIZIA)
Experimental
Hemostatic patch
干预措施: GATT-Patch (currently named ETHIZIA) (Device)
TachoSil
Active Comparator
Hemostatic patch
干预措施: TachoSil (Drug)
结局指标
主要结局
Rate of Hemostasis at 3 Minutes Without Rebleeding at the 10-minute Time Point
时间窗: During surgical procedure, assessed up to 10 minutes after device application
Surface Bleeding Severity Scale 0
次要结局
- Mean Time to Hemostasis (Seconds)(During surgical procedure, assessed up to 10 minutes or up to the time that hemostasis is achieved, whichever occurred last)
- Kaplan-Meier Estimated Distribution of Time to Hemostasis(During surgical procedure, up to the time that hemostasis is achieved)
- Rate of Subjects With Treatment Failure(During surgical procedure)
- Rate of Subjects With Rebleeding After 10 Minutes But Before Subject Closure(During surgical procedure up to patient closure)
- Rate of Subjects With Hemostasis at 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 360, 420, 540 and 600 Seconds(During surgical procedure up to 10 minutes after device application)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder SurgeryIntraoperative BleedingLiver DiseasesGallbladder DiseasesHemorrhage, SurgicalNCT05900037GATT Technologies BV53
已完成
不适用
Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.Acute Upper Gastrointestinal BleedingAcute Upper Gastrointestinal HemorrhageNCT04174989PlasFree Ltd.53
招募中
2 期
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii ComplexHospital-acquired Bacterial PneumoniaVentilator-associated Bacterial PneumoniaNCT06087536Omnix Medical Ltd54
招募中
不适用
Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CREST)Coronary Artery StenosisNCT05606367Shanghai MicroPort Rhythm MedTech Co., Ltd.200
尚未招募
不适用
A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPTCoronary Artery DiseaseNCT03716011JW Medical Systems Ltd2,700